Tag
Extremely high NT-proBNP levels in hospitalized patients often indicate infection rather than heart failure, with a high mortality risk; interpretation requires comprehensive clinical context.
Changes in NT-proBNP levels over three years define heart stress status, which improves cardiovascular and mortality risk prediction in older adults without prior CVD, underscoring its utility in clinical risk stratification.
A post hoc analysis of the ASPREE trial reveals that heart stress, measured by NT-proBNP, significantly alters the relationship between blood pressure and cardiovascular risk in older adults, suggesting a paradigm shift toward biomarker-gui
A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial elig
A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated o
The Hamburg City Health Study reveals that elevated NT-proBNP and hs-cTnI are significantly linked to neurodegeneration and vascular brain injury. These cardiac biomarkers offer a non-invasive pathway for identifying patients at high risk f
In a 3,401-participant community cohort, prolonged EMAT correlated with lower LVEF and worse outcomes but poorly discriminated reduced LVEF and provided no incremental prognostic information beyond NT‑proBNP.
This phase 2 trial shows that volenrelaxin, a long-acting relaxin analog, failed to improve overall congestion or kidney function in HFpEF patients and was linked to worsening congestion and safety signals, despite modest left atrial functi
This systematic review and meta-analysis evaluates NT-proBNP’s accuracy in predicting mortality among ischemic stroke patients, revealing moderate to high prognostic performance with potential clinical utility in risk stratification.
Cardiac biomarkers NT-proBNP and hs-cTnT predict higher risk in asymptomatic severe aortic stenosis, but early TAVR benefits patients regardless of biomarker levels, with greater relative advantage seen in those with lower biomarker concent
The PARAGLIDE-HF trial demonstrates that sacubitril/valsartan significantly reduces NT-proBNP in patients with LVEF >40% and worsening heart failure, regardless of left ventricular hypertrophy or left atrial enlargement, but patients wit
Combining CA125 with NT-proBNP significantly improves prediction of cardiovascular and all-cause mortality, as well as rehospitalization risk in patients with acute heart failure.
